| acute myocardial infarction | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CAST II (early treatment), 1992 | moricizine vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| CAST II (early treatment), 1992 | moricizine for 14 days (n=665) vs. placebo (n=660) | acute myocardial infarction | double blind Parallel groups Sample size: 665/660 Primary endpoint: mortality FU duration: 14 days |
|
| post myocardial infarction | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CAST II (early treatment), 1992 | moricizine vs placebo | | | | | CAST II (late treatment), 1992 | moricizine vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| CAST II (early treatment), 1992 | moricizine for 14 days (n=665) vs. placebo (n=660) | acute myocardial infarction | double blind Parallel groups Sample size: 665/660 Primary endpoint: mortality FU duration: 14 days | | CAST II (late treatment), 1992 | long term moricizine (n=1155) vs. placebo (n=0)
| patient survivor to a myocardial infarctionwhose ventricular premature depolarizations were adequately suppressed by moricizine
| double blind Parallel groups Sample size: 1155/0 Primary endpoint: mortality FU duration:
|
|
